CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 11 enrolled
Drug / intervention
Gemcitabine/Fluorouracil with External Beam Radiationdrug
Likely dose
Gemcitabine/Fluorouracil with External Beam Radiation 200 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00424827
NCT00424827Phase 2Completed
CompareCT.gov

A Phase II Trial of Cetuximab, Gemcitabine, 5-Fluorouracil and Radiation Therapy in Locally Advanced Non-metastatic Pancreatic Adenocarcinoma

University of Massachusetts, Worcester·interventional·Posted Jan 22, 2007·Updated Jun 1, 2017

In Brief

A Phase 2 clinical trial evaluating Gemcitabine/Fluorouracil with External Beam Radiation for Pancreatic Cancer. Completed, enrolled 11 participants.

Detailed Summary

This is an open-label, non-randomized, combination study of cetuximab, gemcitabine, 5-FU, and external beam radiotherapy in patients with locally advanced, non-metastatic pancreatic cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPancreatic Cancer
Countries--
Collaborators--

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 22, 2007
Enrollment StartJun 1, 2006
Primary CompletionDec 1, 2014
TodayJul 2, 2026
Enrollment to primary: 8.5 yearsPosted 19.4 years ago

Interventions

Gemcitabine/Fluorouracil with External Beam Radiationdrug

This protocol will assess the antitumor activity of gemcitabine (200 mg/m2 per week) and cetuximab (400mg/m2 loading dose followed by 250 mg/m2 weekly) when given with continuous infusion 5-FU (200 mg/m2/day/M-F) and daily concurrent external beam radiation therapy (50.4 Gy) in patients with non-metastatic, locally advanced pancreatic carcinoma.